- Home
- TMCR vs AMRN Comparison
TMCR vs AMRN Comparison
Compare TMCR & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMCR | AMRN |
|---|---|---|
| Founded | N/A | 1989 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.0M | 342.8M |
| IPO Year | 2025 | 1998 |
Fundamental Metrics
Financial Performance| Metric | TMCR | AMRN |
|---|---|---|
| Price | $6.40 | $14.13 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 59.8K | 47.7K |
| Earning Date | N/A | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $5.14 | $12.96 |
| 52 Week High | $8.75 | $20.90 |
Technical Indicators
Market Signals| Indicator | TMCR | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 44.43 |
| Support Level | $5.42 | $14.02 |
| Resistance Level | $6.59 | $14.55 |
| Average True Range (ATR) | 0.76 | 0.38 |
| MACD | 0.14 | 0.03 |
| Stochastic Oscillator | 48.13 | 33.75 |
Price Performance
Historical ComparisonAbout TMCR The Metals Royalty Company Inc. Common Stock
The Metals Royalty Co Inc is engaged in the acquisition and management of critical metals and mineral royalties, streams, and other similar interests. It is focused on providing capital to support mineral security and independence in North America in support of accelerating domestic industry growth, including energy, defense, and re-industrialization. The company derives royalty income from its business activities.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.